Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)

The emergence and rapid spread of coronavirus disease 2019 (COVID-19), a potentially fatal disease, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has swiftly led to public health crisis worldwide. Hence vaccines and antiviral therapeutics are an important part of the health...

Descripción completa

Detalles Bibliográficos
Autores principales: Shekhar, Chandra, Nasam, Rajesh, Paipuri, Siva Ramakrishna, Kumar, Prakash, Nayani, Kiranmai, Pabbaraja, Srihari, Mainkar, Prathama S., Chandrasekhar, Srivari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579207/
https://www.ncbi.nlm.nih.gov/pubmed/36276807
http://dx.doi.org/10.1016/j.tchem.2022.100033
Descripción
Sumario:The emergence and rapid spread of coronavirus disease 2019 (COVID-19), a potentially fatal disease, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has swiftly led to public health crisis worldwide. Hence vaccines and antiviral therapeutics are an important part of the healthcare response to combat the ongoing threat by COVID-19. Here, we report an efficient synthesis of nirmatrelvir (PF-07321332), an orally active SARS-CoV-2 main protease inhibitor.

Ejemplares similares